Puerto Rico Pharmaceuticals and Healthcare Report Q4 2017
Puerto Rico's healthcare spending will remain under significant downward pressure aseconomic contraction and fiscal consolidation efforts play out over the next five years. In addition, fundingfor Puerto Rico's medical system under the Affordable Care Act (ACA) will remain in jeopardy, givenrepeal efforts in the US Congress as well as the rising uncertainty over the level of funding once the onetimeMedicaid provisions granted to the island under ACA expires in 2018. Meanwhile, despitedeteriorating demographics and a protracted internal devaluation, Puerto Rico's large pharmaceuticalmanufacturing industry will continue to attract some level of investment, given its facilitated access to theUS market and tax incentives.
Headline Expenditure Projections
Pharmaceuticals: USD3.83bn in 2016 to USD3.87bn in 2017; +1.1%. Forecast broadly in line with thelast quarter.
Healthcare: USD8.37bn in 2016 to USD8.71bn in 2017; +4.0%. Forecast in line with the last quarter.Latest Updates
As of information reported in September 2017, the government, some hospitals and non-profits areoffering incentives to medical personnel in order to try to prevent the exodus of qualified medicalprofessionals from the island. The outflow of trained personnel has been exacerbated by the economicrecession.